Emergence of Lipid-Based Vesicular Carriers as Nanoscale Pharmacotherapy in Rheumatoid Arthritis

Author(s): Mahfoozur Rahman, Sarwar Beg, Gajanand Sharma, Firoz Anwar, Vikas Kumar.

Journal Name: Recent Patents on Nanomedicine (Discontinued)

Volume 5 , Issue 2 , 2015

Submit Manuscript
Submit Proposal

Graphical Abstract:


Abstract:

Rheumatoid arthritis (RA) is an immune mediated joint based dreadful inflammatory disorder, which is characterized by joint destruction, swelling, pain and remission; it resulted to shorten lifespan and increased mortality rates. Current treatment approaches and their advancement have gained much attention in the prevention of RA and improvement in the many RA patients life. Despite their significant merits, still major drawbacks remain like requirement of high dose, disease remission and prominent side effects. Emergences of lipid based vesicular nanocarriers, including liposomes, stealth liposomes, transfersomes, ethosomes, and niosomes etc., are designed to deliver anti-rheumatic drug to the specific sites via enhanced permeability and retention (EPR) and active targeting to achieve desirable therapeutic effect. Whereas it avoids systemic and non target associated side effects. In addition to this, several US and others patents on liposomes in RA are also included. Therefore, the present review gives an exhaustive account on recent advancement in lipid containing vesicular nanocarrier’s drug delivery in the treatment of RA.

Keywords: Ethosomes, liposome, NSAIDs, Niosomes, rheumatoid arthritis, transferosomes.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 5
ISSUE: 2
Year: 2015
Page: [111 - 121]
Pages: 11
DOI: 10.2174/1877912305666150616215800
Price: $58

Article Metrics

PDF: 20